Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas

Sameer Mir; Abhilash Venugopalan; Jingli Zhang; Nishanth Ulhas Nair; Manjistha Sengupta; Manakamana Khanal; Chaido Stathopoulou; Qun Jiang; Raffit Hassan

doi:10.1002/ctm2.70057

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (11) : e70057 DOI: 10.1002/ctm2.70057

RESEARCH ARTICLE

Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas

Author information +

History +

PDF

Abstract

	•Mesothelin expression is significantly higher in gastric and colorectal cancers than normal tissues.
	•hYP218 CAR T cells demonstrate strong anti-tumour activity against mesothelin-positive gastric and colorectal carcinomas.
	•Activated hYP218 CAR T cells persist in the tumour microenvironment and retain their cytotoxic activity.
	•Addition of pembrolizumab in larger tumours enhance CAR T cell efficacy.

Keywords

anti-PD1 / CAR T cell / colorectal cancer / gastric cancer / mesothelin / pembrolizumab / xenograft cancer model

Cite this article

Download citation ▾

Sameer Mir,Abhilash Venugopalan,Jingli Zhang,Nishanth Ulhas Nair,Manjistha Sengupta,Manakamana Khanal,Chaido Stathopoulou,Qun Jiang,Raffit Hassan. Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas. Clinical and Translational Medicine, 2024, 14(11): e70057 DOI:10.1002/ctm2.70057

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2024. This article is a U.S. Government work and is in the public domain in the USA. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.